Alpha Tau Medical (DRTS) Q2 2026 earnings summary

Executive summary

• Achieved major milestones: first regulatory approval in Japan for Alpha DaRT, completion of U.S. pivotal ReSTART trial enrollment, and strategic U.S. commercialization partnership with Tolmar for prostate cancer.

• Presented strong clinical data in glioblastoma, pancreatic, and head & neck cancers, including 100% objective response rate in a pembrolizumab combination study.

• Cash, cash equivalents, short-term deposits, and restricted deposits totaled $104.8 million as of June 30, 2026, providing at least two years of runway.

Financial highlights

• Research and development expenses rose to $20.9 million for the six months ended June 30, 2026, up from $14.2 million year-over-year, driven by increased compensation, clinical activity, and raw materials.

• General and administrative expenses increased to $5.7 million from $3.9 million, mainly due to higher compensation and professional fees.

• Marketing expenses decreased to $0.6 million from $0.9 million, reflecting lower employee compensation.

• Financial expenses, net, surged to $41.4 million from $0.3 million income, primarily due to warrant liability remeasurement as share prices rose.

• Net loss for the period was $68.8 million ($0.76/share), compared to $18.8 million ($0.25/share) in the prior year period.

• Cash and equivalents increased to $104.8 million from $76.9 million at year-end 2025, supported by equity raises and milestone payments.

Outlook and guidance

• Management expects continued expense growth as clinical trials expand, manufacturing scales, and commercialization efforts increase.

• Cash runway is projected to cover at least two years of operations.

• Key upcoming milestones include completion of pivotal trials in pancreatic cancer (IMPACT), glioblastoma (REGAIN), and cSCC (ReSTART), with top-line data expected late 2026 or early 2027.